Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

With morale at a low point, biotech and pharma CEOs are cautiously optimistic about the incoming Trump administration.

Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to ...